Information Provided By: 
Fly News Breaks for March 20, 2015
SHPG
Mar 20, 2015 | 08:12 EDT
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
News For SHPG From the Last 2 Days
There are no results for your query SHPG
